22q11.2 deletion syndrome (22q11.2DS) is the most common chromosomal microdeletion disorder, estimated to result mainly from de novo non-homologous meiotic recombination events occurring in ...
BASEL, Switzerland, July 9, 2018 /PRNewswire/ -- Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, announced today that it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results